Regenxbio reported a quarterly loss of $1.72 per share, wider than the Zacks Consensus Estimate loss of $1.36 and sharply worse than earnings of $0.12 per share a year ago. The miss highlights deteriorating profitability and is likely to weigh on investor sentiment, though the article provides no revenue or guidance details.
Regenxbio reported a quarterly loss of $1.72 per share, wider than the Zacks Consensus Estimate loss of $1.36 and sharply worse than earnings of $0.12 per share a year ago. The miss highlights deteriorating profitability and is likely to weigh on investor sentiment, though the article provides no revenue or guidance details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
